Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment of Different Tetracycline Doses

Summary

The researchers collect treatment-naive H.pylori-positive patients from the outpatient clinic. The subjects were randomized to receive a dose and frequency of tetracycline 500mg tid or qid of bismuth quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13C-urea breath test. Calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.

Conditions

• Helicobacter Pylori Infection

Interventions

DRUG

Amoxicillin

Included in quadruple eradication medication.

DRUG

Tetracycline tid

Included in quadruple eradication medication.

DRUG

Tetracycline qid

Included in quadruple eradication medication.

DRUG

Bismuth Potassium Citrate

Included in quadruple eradication medication.

DRUG

Colloidal Bismuth Pectin

Included in quadruple eradication medication.

DRUG

Esomeprazole 20mg

Included in quadruple eradication medication.

Sponsors & Collaborators

• Peking University Care Luzhong Hospital

  collaborator OTHER

• Yuncheng Traditional Chinese Medicine Hospital

  collaborator OTHER

• Taierzhuang District People's Hospital

  collaborator OTHER

• Zhengzhou Central Hospital

  collaborator OTHER

• Zibo Central Hospital

  collaborator OTHER_GOV

• Shandong University

  lead OTHER

Principal Investigators

• Xiuli Zuo, MD,PhD · Qilu Hospital of Shandong University

Study Design

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Max Age

70 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2022-07-01

Primary Completion

2024-02-01

Completion

2024-02-01

Countries

• China

Study Locations